Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + ancestim
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Lenalidomide is a thalidomide derivative and immunomodulatory agent used primarily to treat multiple myeloma, certain types of myelodysplastic syndromes (MDS), mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. It works by modulating the immune system, inhibiting angiogenesis (the formation of new blood vessels in tumors), and directly killing abnormal cells in the bone marrow. Lenalidomide inhibits targets such as tumor necrosis factor alpha and cereblon[1][2][5]. Ancestim is a recombinant human stem cell factor used to increase the number and mobilization of peripheral blood progenitor cells for collection during autologous peripheral blood progenitor cell transplantation. It acts by stimulating hematopoietic stem cells via the c-Kit receptor[3][6]. The combination may be considered in clinical settings where both immunomodulation/anti-cancer effects (lenalidomide) and enhanced stem cell mobilization (ancestim) are desired.
- Other names
- none
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)CRBN (Cereblon)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on lenalidomide + ancestim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + ancestim.